Lantern Pharma Inc. Unveils AI Tool to Predict Cancer Drug Combination Efficacy

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biotechnology company, has launched an innovative artificial intelligence module aimed at predicting the efficacy of cancer treatment combinations. This module, part of the company's RADR(R) platform, focuses on therapies involving DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis). By analyzing genomic, transcriptomic, and clinical data, the AI tool can forecast treatment synergy and patient response, offering a groundbreaking approach to personalized cancer care.

The development of this predictive algorithm was informed by a comprehensive review of 221 clinical trials, highlighting the potential of non-PARP DDRi combinations with DNA-damaging agents in specific cancer subtypes. This technology has already played a pivotal role in designing Lantern’s FDA-cleared Phase 1B/2 trial for triple-negative breast cancer, showcasing its immediate applicability and potential to revolutionize treatment strategies.

With the global market for combination cancer therapies expected to exceed $50 billion by 2030, Lantern Pharma's AI module arrives at a critical juncture. The company is currently exploring licensing opportunities to make this technology available for broader oncology use, which could significantly impact the development and customization of cancer treatments worldwide.

For more information on Lantern Pharma's advancements and updates, visit https://ibn.fm/LTRN.